JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin.

OBJECTIVE: To study the effect of long-term treatment during gestation with heparin on the incidence of osteoporotic fractures and thromboembolic recurrence.

STUDY DESIGN: Long-term subcutaneous prophylaxis with heparin twice daily in pregnancy was prescribed for 184 women, during a decade because of an increased risk of thromboembolism. The dosage of heparin was adjusted to anti-factor Xa activity or activated partial thromboplastin time and different regimens were given, depending on the risk of recurrence.

RESULTS: For the total group the mean dosage of heparin ranged from 13,000 to 40,000 IU per 24 hours (mean 19,100 IU per 24 hours), and the average duration of treatment was 25 weeks. Symptomatic osteoporotic fractures of the spine occurred post partum in four women, for whom the mean dosage of heparin ranged from 15,000 to 30,000 IU per 24 hours (mean 24,500 IU per 24 hours), and the duration of treatment ranged from 7 to 27 weeks (mean 17 weeks). In spite of prophylaxis with heparin, thromboembolic complications occurred in five women. They had either nonsatisfactory concentrations of heparin according to our regimen or were later diagnosed as having a coagulation disorder known to increase the risk of thromboembolism.

CONCLUSION: Osteoporotic vertebral fractures were found in 2.2% of the women, and a relationship to the amount of heparin was indicated, although fractures were not avoided during low-dose, short-term prophylaxis. Recurrence of thromboembolism occurred in 2.7% of the patients, but if a strict heparin adjustment had been performed, recurrence could probably have been prevented.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app